Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial - - Data presented at AACR 2023 supports ...

Looking for more dividends? Here are four blue-chip stocks that recently raised theirs. The post 4 Attractive Singapore ...

Create rich, interactive reports with visual analytics at your fingertips—for free. Dig deeper into data and find patterns you may have otherwise missed that lead to actionable insights. Use features ...

Download Google Chrome for PC to use an essential tool on the Internet. The favorite browser for over a billion users. Every year its market share goes rocket high, and that's despite being the latest ...